Merck & Company Inc (MRK)vsNexalin Technology Inc. (NXL)
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
NXL
Nexalin Technology Inc.
$0.36
+2.42%
HEALTHCARE · Cap: $8.34M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 21551698% more annual revenue ($65.01B vs $301,650). MRK leads profitability with a 28.1% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
NXL
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Intrinsic value data unavailable for NXL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Revenue surging 533.0% year-over-year
Reasonable price relative to book value
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -221.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : NXL
The strongest argument for NXL centers on Revenue Growth, Price/Book. Revenue growth of 533.0% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : NXL
The primary concerns for NXL are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
MRK profiles as a value stock while NXL is a hypergrowth play — different risk/reward profiles.
NXL carries more volatility with a beta of 4.23 — expect wider price swings.
NXL is growing revenue faster at 533.0% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 28/100), backed by strong 28.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Nexalin Technology Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Nexalin Technology Inc. is an innovative leader in the medical technology industry, dedicated to transforming the treatment of neurological and psychiatric disorders through its proprietary transcranial electrical stimulation devices. These non-invasive therapies target conditions such as anxiety, depression, and substance addiction, reflecting the company's commitment to advancing mental health solutions. With a robust foundation in research and a clear strategic focus on improving patient outcomes, Nexalin is well-positioned to leverage the increasing demand for cutting-edge healthcare innovations, indicating significant growth potential in the dynamic digital health marketplace.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?